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Risk of medication overuse headache
across classes of treatments for acute
migraine
Kristian Thorlund1,2*, Christina Sun-Edelstein3, Eric Druyts2,4, Steve Kanters2,5, Shanil Ebrahim1, Rahul Bhambri6,
Elodie Ramos6, Edward J. Mills1,2, Michel Lanteri-Minet7,9 and Stewart Tepper8
Abstract
Background: The most commonly prescribed medications used to treat migraine acutely are single analgesics,
ergots, opioids, and triptans. Due to varying mechanisms of action across drug classes, there is reason to believe
that some classes may be less likely than others to elicit Medication Overuse Headache (MOH) than others. We
therefore aimed to determine whether certain classes of acute migraine drugs are more likely to elicit MOH than
others.
Methods: A comprehensive systematic literature was conducted to identify studies of varying designs that reported
on MOH within the considered treatment classes. Only studies that reported MOH according to the International
Classification of Headache Disorders (ICHD) were considered. Since no causal comparative design studies were
identified; data from prevalence studies and surveys were retrieved. Prevalence-based relative risks between treatment
classes were calculated by integrating both medication overuse and medication use from published studies. For each
pair wise comparison, pooled relative risks were calculated as the inverse variance weighted average.
Results: A total of 29 studies informed the relative risk between treatment classes, all of which reported country-specific
data. Five studies reported country-specific medication use data. For triptans versus analgesics the study relative risks
generally favored triptans. The pooled relative risk was 0.65 (i.e., relative risk reduction of 35 %). For ergots versus
analgesics, a similar trend was observed in favor of ergots with a relative risk of 0.41. For triptans versus ergots,
the direction of effect was mixed, and the pooled relative risk was 1.07. Both triptans and ergots appeared favorable
when compared to opioids, with pooled relative risks of 0.35 and 0.76, respectively. However, the evidence was limited for
these comparisons. Analgesics and opioids also appeared to yield similar risk of MOH (pooled relative risk 1.09).
Conclusion: Our study suggests that in patients receiving acute migraine treatment, analgesics and opioids are
associated with a higher risk of developing MOH compared with other treatments. These findings provide incentive for
better monitoring of use of analgesics and opioids for treating acute migraine, and suggest possible clinical preference
for use of so-called “migraine-specific” treatments, that is, triptans and ergots.
Background
Medication-overuse headache (MOH) is caused by overuse
of medications for migraines or other pain disorders.
According to the International Classification of Headache
Disorders, 3rd Edition, Beta (ICHD-3), MOH is defined as
headache occurring on 15 or more days per month
developing as a consequence of regular overuse of acute or
symptomatic headache medication (on 10 or more, or 15
or more days per month, depending on the medication) for
more than 3 months [1].
MOH manifests as increased frequency and intensity
of headaches or migraine attacks and enhanced sensitivity
to stimuli that elicit these episodes [2] Although the
mechanisms underlying MOH are not fully elucidated, it
is hypothesized that repeated medication use could elicit
increased headache attacks as a consequence of neuronal
plasticity that may increase responsiveness to triggers. The
* Correspondence: kthorlund@redwoodoutcomes.com
1Department of Clinical Epidemiology & Biostatistics, McMaster University,
Hamilton, ON, Canada
2Redwood Outcomes, 302-1505 2nd Ave. West, Vancouver, BC, Canada
Full list of author information is available at the end of the article
The Journal of Headache
                           and Pain
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
Thorlund et al. The Journal of Headache and Pain  (2016) 17:107 
DOI 10.1186/s10194-016-0696-8
prevalence of MOH is 1–2 % in the general population
worldwide, and because of the estimated socio-economic
cost, it is likely to be the most costly neurological disorder
known [3–6].
Commonly prescribed medications for migraines may
include analgesics, ergots, opioids, and triptans. Due to
varying mechanisms of action across drug classes, there
is reason to believe that some classes may be less likely
than others to elicit MOH. Because of the estimated
socio-economic burden of MOH, it is therefore import-
ant to establish which drug class generally is least likely
to elicit MOH.
The aim of this study was therefore to determine whether
certain classes of acute migraine drugs are more likely to
elicit MOH than others. To achieve this, we performed a
comprehensive systematic literature review of available
evidence and, to the extent data allowed, extrapolated the
comparative risks of MOH associated with available drug
classes.
Methods
Eligibility criteria
Eligible studies could be either observational or clinical
(randomized or non-randomized) in nature. Only studies
that included adults 18 years of age and older who were
suffering from acute migraine were eligible. Eligible studies
must have reported MOH by treatment class (i.e. analgesic,
ergot, opioid, or triptan), and according to versions of
ICHD-2 [1, 7–9].
Search strategy
In consultation with an academic medical librarian, we
conducted a systematic search of the medical literature
using MEDLINE, EMBASE, and the Cochrane Controlled
Trials Register (from inception to March 24, 2014). The
search strategy was sensitive and broad, consisting of the
following: ‘medication overuse headache’ and ‘migraine’.
Conference abstracts provided through the EMBASE
search were also reviewed to determine if there were
relevant studies recently completed. Additionally, hand
searches of the bibliographies of published systematic
reviews and health technology assessments were per-
formed. All searches were performed independently, in
duplicate.
Data extraction
We extracted data on the total number of patients, the
number of patients with MOH by treatment class (i.e.
analgesics, ergots, opioids, and triptans), MOH diagnostic
criteria, and the country/region of each study. These data
were extracted from the baseline characteristics of the
studies. Two reviewers independently extracted and re-
corded all data in a Microsoft Excel spreadsheet. All data
extraction were then checked by a third reviewer.
Materials
Out of 443 abstracts reviewed, a total of 29 studies were
eligible [10–39]. Additional file 1: Figure S1 shows the
flow chart, and Additional file 1: Table S1 show the list
of studies excluded following full-text review with ac-
companying reason for exclusion. Table 1 presents the
characteristics of the included studies. All included stud-
ies had been published since the year 2004, when the
ICHD-2 was first released. Eleven of the included studies
adhered to the definition of MOH in version 1 of the
ICHD-2, whereas 9 studies adhered to the revision put
forward in 2005, and 9 studies adhered to the appendix
put forward in 2006. No studies made use of ICHD-3,
released in beta in 2013. All studies took place in Europe
(1 in Denmark, 3 in France, 2 in Germany, 19 in Italy, 2 in
Norway, 1 in Spain, and 1 in Sweden). Two studies were
population based, the remaining were based out of a clinical
setting (i.e., investigator headache centers, hospital depart-
ments of neurology, of headache and pain clinics).
In general, the included studies reported on use of
treatment classes, but did not distinguish which indi-
vidual agent or agents (e.g., sumatriptan or eletriptan
for triptans) had been administered to patients. Thus,
analysis by individual agents was not possible. However,
since all eligible studies were published between 2006
and 2013, it is reasonable to assume that most patients
receiving ergots received dihydroergotamine (DHE) and
not the older ergotamine tartrate.
All studies reported MOH as prevalence estimates within
included study population; no study reported MOH as an
outcome. All included studies were either observational
(prospective or retrospective), clinical cohorts, or popula-
tion surveys.
Data considerations
As indicated in section 3.4, no trials or observational
studies looking at multiple migraine interventions re-
ported development of MOH as an outcome. For this
reason, the comparison between interventions had to
be based on studies reporting prevalence estimates of
MOH. While relatively few available studies were specific-
ally designed to estimate prevalence, several still provided
data on the proportion of patients using each of the inter-
ventions that had developed MOH. For example, several
survey studies reported in their baseline table the number
and proportion of enrolled patients with MOH. Other
publications described the characteristics of migraine pa-
tients in one or more clinics, which included the number
and proportion of patients with MOH. To justify inclusion
of studies not designed to estimate prevalence, we made
the assumption that prevalence estimates were not con-
founded by the designs of these studies. We verified that
the eligibility criteria in these studies did not include criteria
related to MOH.
Thorlund et al. The Journal of Headache and Pain  (2016) 17:107 Page 2 of 9
Since the prevalence of MOH is highly correlated with
the prevalence of drug dispensing, prevalence estimates
do not provide a good basis for comparison of risk of
MOH associated with the different interventions. For
example, triptans are prescribed more frequently than
ergots, and so we expect to see higher numbers of triptan-
related MOH occurrences than ergot-related MOH occur-
rences. To form a fair basis for comparisons of the relevant
interventions, it is therefore also necessary to know the fre-
quency of treatment use. These were estimated post-hoc by
a systematic review of the literature, and were incorporated
in the calculations of comparative risk of MOH. To this
end, we systematically searched MEDLINE and EMBASE
for population-based studies providing estimates of medica-
tion use prevalence for the countries/regions represented in
the eligible MOH prevalence studies.
The prevalence of medication use for migraine was
derived from 5 studies identified in our literature review
(See Table 2) [23, 40–43]. Because the data on medication
prevalence use was limited, some assumptions needed to
be made. For all countries, the prevalence of opioid
use among those with migraine was not available. The
closest evidence of opioid use prevalence that we iden-
tified was a Swedish study including chronic headache
patients. This study yielded an opioid use prevalence
of 4.1 %. Since use of opioids is known to be low in
Europe (which is where all included studies came
from) and since we believed it reasonable to assume
opioid use among chronic daily headache patients
would likely be higher than opioid use among acute
migraine patients, we assumed an opioid use preva-
lence of 2 % for all included studies.
Table 1 Summary of study characteristics
Study Country Diagnosis
classification
Study
setting
No.
patients
No. medication overuse headache
Analgesics Ergots Opioids Triptans
Altieri et al. 2009 [11] Italy ICHD-2 [7] Clinic 27 11 NR NR 4
Ayzenberg et al. 2008 [12] Germany ICHD-2 [7] Clinic 29 14 NR NR 15
Biagianti et al. 2012 [13] Italy ICHD-2 Revised [8] Clinic 52 26 NR NR 20
Boe et al. 2007 [14] Norway ICHD-2 Appendix [7] Clinic 100 20 1 NR 23
Coppola et al. 2010 [15] Italy ICHD-2 Appendix [7] Clinic 29 10 NR NR 9
Cupini et al. 2009 [16] Italy ICHD-2 Appendix [7] Clinic 33 NR 1 NR 4
Di Lorenzo et al. 2009 [17] Italy ICHD-2 [7] Clinic 107 18 NR NR 29
Donnet et al. 2009 [18] France ICHD-2 [7] Population 320 157 25 29 64
Dousset et al. 2013 [19] France ICHD-2 Appendix [7] Clinic 42 8 1 0 9
Galli et al. 2011 [20] Italy ICHD-2Appendix [7] Clinic 82 21 2 3 22
Gambini et al. 2013 [21] Italy ICHD-2 Revised [8] Clinic 63 33 NR NR 21
Gomez-Beldarrain et al. 2011 [22] Spain ICHD-2Revised [8] Clinic 42 25 NR NR 3
Hagen et al. 2009 [23] Norway ICHD-2 Appendix [7] Clinic 56 18 NR 14 17
Jonsson et al. 2011 [6] Sweden ICHD-2 Appendix [7] Population 799 517 7 33 66
Lorenzo et al. 2012 [24] Italy ICHD-2 Appendix [7] Clinic 43 17 NR NR 8
Pageler et al. 2008 [25] Germany ICHD-2 [7] Clinic 20 1 3 NR 5
Perrotta et al. 2010 [26] Italy ICHD-2 [7] Clinic 31 11 NR NR 19
Perrotta et al. 2012 [27] Italy ICHD-2 [7] Clinic 27 4 NR NR 6
Radat et al. 2013 [28] France ICHD-2 [7] Clinic 17 2 NR 2 4
Rainero et al. 2006 [29] Italy ICHD-2 [7] Clinic 18 NR 2 NR 3
Relja et al. 2006 [30] Italy ICHD-2 [7] Clinic 101 38 9 0 12
Rossi et al. 2006 [31] Italy ICHD-2 Revised [8] Clinic 118 63 3 NR 24
Rossi et al. 2011 [32] Italy ICHD-2 Revised [8] Clinic 100 57 1 NR 23
Sances et al. 2010 [33] Italy ICHD2 Revised [8] Clinic 172 42 5 5 50
Sandrini et al. 2011 [34] Italy ICHD-2 Appendix [7] Clinic 56 23 2 NR 20
Terrazzino et al. 2010 [35] Italy ICHD-2 Revised [8] Clinic 227 79 2 1 32
Trucco et al. 2010 [36] Italy ICHD-2Revised [8] Clinic 70 18 0 NR 9
Valguarnera et al. 2010 [37] Italy ICHD2 [7] Clinic 95 20 2 2 30
Zeeberg et al. 2006 [38] Denmark ICHD2 Revised [8] Clinic 216 63 8 12 43
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Analysis
For each study we first calculated the proportion of patients
with MOH in each treatment class, using the total number
of patients as the denominator for both proportions. Subse-
quently the relative risk was calculated between each pair
of treatment classes. As mentioned in the previous section,
these relative risks are highly driven by the proportion of
patients that received each treatment. For this reason, we
applied an adjustment to the relative risk estimates. In par-
ticular, we first estimated the ratio with which treatments
are being prescribed in clinical practice from prevalence
estimates of medication use, and multiplied the inverse of
this ratio to the above-obtained relative risks (see Table 2).
Further, sensitivity analysis assuming an 8 % medication
use prevalence for opioids, was conducted.
The adjusted study relative risks were pooled for each
comparison in a fixed-effect meta-analysis. A fixed-effect
model was used to provide a fair weighted average of
studies. The meta function in R.v.3.0 was used to pool
results and produce forest plots. While this function by
convention produces 95 % credible intervals, one should
only focus on the relative risk estimates and the weighted
(pooled) average relative risk, since confidence intervals
address sampling error and therefore are not valid under
the above adjustments.
Results
Triptans versus analgesics
Twenty-five studies informed MOH for both triptans and
analgesics in countries where medication use prevalence
Table 2 Prevalence of medication use for episodic migraine in Europe (column 2) and the applied adjustment factors in calculating
MOH prevalence and risk ratios (columns 3–6)
Country/Region Drug class (Prevalence, %) Analgesics Ergotamines Opioids Triptans
Denmark [41] Analgesics (NA) – NA NA NA
Ergotamines (NA) NA – NA NA
Opioids (2.0) NA NA – 1:13 (0.08)
Triptans (26.0) NA NA 13:1 (13.0) –
France [40, 42] Analgesics (12.0) – 4:1 (4.00) 6:1 (6.0) 6:10 (0.58)
Ergotamines (3.0) 1:4 (0.25) – 3:2 (1.50) 1:7 (0.14)
Opioids (2.0) 1:6 (0.17) 2:3 (0.67) – 1:10 (0.10)
Triptans (20.8) 10:6 (1.73) 7:1 (6.93) 10:1 (10.4) –
Germany [40, 42] Analgesics (31.0) – 9:2 (4.43) 15:1 (15.0) 2:1 (2.14)
Ergotamines (7.0) 2:9 (0.23) – 7:2 (3.50) 1:2 (0.48)
Opioids (2.0) 1:15 (0.06) 2:7 (0.29) – 1:7 (0.14)
Triptans (14.5) 1:2 (0.47) 2:1 (2.07) 7:1 (7.25) –
Italy [40, 42] Analgesics (12.0) – 12:3 (3.75) 6:1 (6.00) 4:5 (0.79)
Ergotamines (3.2) 3:12 (0.27) – 8:5 (1.60) 1:5 (0.21)
Opioids (2.0) 1:6 (0.17) 5:8 (0.63) – 1:8 (0.13)
Triptans (15.1) 5:4 (1.25) 5:1 (4.72) 8:1 (7.55) –
Norway [43] Analgesics (NA) – NA NA NA
Ergotamines (NA) NA – NA NA
Opioids (2.0) NA NA – 1:19 (0.05)
Triptans (37.0) NA NA 19:1 (18.5) –
Spain [40] Analgesics (16.4) – 4:5 (0.82) 8:1 (8.20) 1:2 (0.56)
Ergotamines (20.0) 5:4 (1.22) – 10:1 (10.0) 2:3 (0.69)
Opioids (2.0) 1:8 (0.12) 1:10 (0.10) – 1:15 (0.07)
Triptans (29.1) 2:1 (1.77) 3:2 (1.46) 15:1 (14.6) –
Sweden [23] Analgesics (NA) – NA NA NA
Ergotamines (NA) NA – NA NA
Opioids (2.0) NA NA – 3:19 (0.16)
Triptans (26.0) NA NA 19:3 (6.34) –
The medication use prevalence estimates presented in parenthesis next to treatment classes in column 2 are taken from included prevalence literature. The ratios
(e.g. 3:1) presented in columns 3–6 are approximate ratios of prevalence of use of one medication over another. These ratios are also the adjustments factors
multiplied to the unadjusted ratios of MOH for each study to account for the missing information about patients at risk on each medication within each study
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estimates were also available for both. Adjusted relative
risks from these studies are presented in Fig. 1a. Fourteen
studies yielded relative risks in favor of triptans, with
adjusted relative risks varying from 0.12 to 0.94. In 9 of
these 14 studies the relative risk was statistically signifi-
cant. Eleven studies yielded adjusted relative risks in favor
of analgesics, with adjusted relative risk estimates varying
from 1.05 to 5.00. The fixed-effect weighted average ad-
justed relative risk was 0.65, thus suggesting an average
35 % relative risk reduction of MOH associated with trip-
tans compared with analgesics.
Triptans versus ergots
Fourteen studies informed MOH for both triptans and
ergots in countries where medication use prevalence
estimates were also available for both. Adjusted relative
risks from these studies are presented in Fig.1b. Four
studies yielded adjusted relative risk estimates in favor of
triptans, two yielded no difference (i.e. relative risk of
1.00), and eight studies yielded adjusted relative risk esti-
mates in favor of ergots. The fixed-effect weighted aver-
age relative risk was 1.07.
Triptans versus opioids
Eleven studies informed MOH for both triptans and
opioids in countries where medication use prevalence
estimates were also available for both. Adjusted relative
risks from these studies are presented in Fig.1c. Five
studies yielded adjusted relative risk estimates in favor
of triptans, one study suggested no difference, and five
studies yielded relative risk estimates in favor of opioids.
The fixed-effect weighted average adjusted relative risk
was 0.35, suggesting an average 65 % relative risk reduc-
tion of MOH with triptans compared with opioids.
Ergots versus analgesics
Twelve studies informed MOH for both ergots and
analgesics in countries where medication use preva-
lence estimates were also available for both. Adjusted
relative risks from these studies are presented in Fig.2a.
Eleven of these yielded adjusted relative risk estimates in
favor of ergots, and only one small study cell with a zero
cell in the analgesics arm yielded a relative risk estimate in
favor of analgesics. Among the former 11, adjusted relative
risks varied between 0.07 and 0.90. The fixed-effect
weighted average adjusted relative risk was 0.41, suggesting
an average 59 % relative risk reduction of MOH with ergots
compared with analgesics.
Ergots versus opioids
Seven studies informed MOH for both ergots amines
and opioids. Adjusted relative risks from these studies
are presented in Fig.2b. Four of these studies yielded
adjusted relative risk estimates in favor of ergots (ranging
from 0.33 to 0.60), one yielded an adjusted relative risk
estimate of 1.00 (i.e., no difference), and two studies, both
with zero cells in the opioids arm, yielded relative risk
estimates in favor of opioids. The fixed-effect weighted
average relative risk was 0.76, suggesting an average
24 % relative risk reduction of MOH with ergots com-
pared with opioids. As noted, this likely reflects mostly
DHE use rather than ergotamine tartrate.
Analgesics versus Opioids
Nine studies informed MOH for both analgesics and
opioids. Adjusted relative risks from these studies are
presented in Fig.2c. Three studies yielded adjusted rela-
tive risk estimates in favor of analgesics, and six studies
yielded relative adjusted risk estimates in favor of opioids.
The fixed-effect weighted average adjusted relative risk
was 1.09, suggesting an average 9 % increased risk of
MOH with analgesics compared with opioids.
Discussion
Our analysis aimed to evaluate rates of MOH depending
on the type of medication used. We found a considerably
higher rate of MOH associated with analgesics in compari-
son to triptans and ergots. Our findings also suggest that
opioids are either associated with a higher or similar risk of
MOH compared to triptans and ergots, but evidence was
more limited for these comparisons. These findings should
be of interest to patients, clinicians, and policy-makers as
many patients may self-medicate, and the magnitude of
analgesic use is potentially higher than what has generally
been observed in population-based studies.
There are strengths and limitations to our analysis that
should be considered. Strengths of this study include
our extensive searching to complete the largest and
first systematic review of MOH associated with mi-
graine pharmacotherapies. We used an approach that
integrated evidence on medication overuse and medi-
cation use, the first such effort of which we are aware.
The employed approach further strengthens compar-
isons between interventions, since all studies provide
data on at least two interventions, and so allows for
the analysis to retain within-study validity. Studies in-
cluded had to use the ICHD-2 criteria or later, and thus
removed most uncertainty about the appropriateness of
the MOH definition, which was particularly variable in
older studies. However, this eligibility criterion also came
with the limitation that the American Migraine Prevalence
and Prevention (AMPP) study was not eligible [35]. In
fact, no US studies were eligible under the employed cri-
teria. Therefore, generalizability of our findings to the US
population is somewhat limited.
We relied instead on observational studies reporting
a mix of pseudo-risk data and medication use data to
approximate the relative risk between interventions.
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Fig. 1 Forest plots and weighted average estimate for the relative risk of MOH for the three comparisons: a triptans versus analgesics; b triptans
versus ergots; and c triptans versus opioids
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Fig. 2 Forest plots and weighted average estimate for the relative risk of MOH for the three comparisons: a ergots versus analgesics; b ergots
versus opioids; and c analgesics versus opioids
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The analytical approached employed to synthesize re-
sults from these data relied on assumption that are ar-
guably strong. There may therefore be controversy as
to where the evidence fits in the evidence hierarchy.
Recognizing the challenges of conducting these evalua-
tions, and given the consistency of our study findings,
the investigators believe this systematic review of obser-
vational studies provides strong inferences about the
causative factors of MOH. The heterogeneity between
studies was generally low, in spite of the observational
nature of the included studies and the additional uncer-
tainty one might expect from the employed medication
use prevalence adjustments. Also, the findings of the
individual pair-wise meta-analysis added up ‘indirectly’.
For example, the direct comparison of triptans and
ergots showed similar risk of MOH, and both drug
classes had similar relative risk estimates when com-
pared with analgesics (0.65 and 0.41). These consisten-
cies thus add considerable confidence to the findings of
the analyses.
There are several possible reasons for our finding in-
creased MOH associated with analgesic and opioid use
and less so with triptans and ergots. Analgesics and opi-
oids typically work via targeting pain receptors. On the
other hand, both triptans and ergots share serotonergic
agonist activity and are vasoconstrictors. Furthermore,
analgesics are frequently used in an over-the-counter
manner whereby patients self-administer and may do so
without the supervision of a clinician. Triptans are, for
the most part, prescription medications, and overuse
may be better monitored than analgesics. In those coun-
tries in which triptans are available without a prescription
(e.g. UK, Germany), quantity limits may prevent tendency
to overuse.
While our findings are in line with current clinical
guidelines and prejudice in favor of targeted migraine-
specific pharmacotherapy, they should still only be inter-
preted as exploratory due to their observational nature.
Further, the inclusion of only European studies limits our
ability to extrapolate the findings to other global regions.
In summary, our study suggests that in patients with
acute episodic migraine, the rate of MOH associated with
analgesics and opioids is considerably higher than the rate
of MOH associated with triptans and ergots. These findings
should be of interest to patients, clinicians, and policy-
makers, as many patients self-medicate, and the magnitude
of analgesic use is potentially higher than what has gener-
ally been observed in population-based studies.
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